Across TCGA pan-cancer cohorts, ACTG1P25 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ACTG1P25 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher ACTG1P25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTG1P25 expression acts as an unfavorable survival marker.
THYM are the cancer types where ACTG1P25 Mutation most reproducibly stratifies survival.